JamaicaTuberculosis profile
Population  2015 2.8 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.24 (0.24–0.24)
Mortality (HIV+TB only) <0.01 (<0.01–0.014) 0.21 (0.05–0.49)
Incidence  (includes HIV+TB) 0.13 (0.099–0.16) 4.6 (3.5–5.8)
Incidence (HIV+TB only) 0.031 (0.023–0.039) 1.1 (0.83–1.4)
Incidence (MDR/RR-TB)** <0.01 (0–<0.01) 0.09 (0–0.24)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females <0.01 (<0.01–<0.01) 0.034 (0.015–0.053) 0.04 (0.018–0.061)
Males <0.01 (<0.01–<0.01) 0.083 (0.063–0.1) 0.089 (0.066–0.11)
Total 0.011 (<0.01–0.015) 0.12 (0.1–0.13) 0.13 (0.099–0.16)
TB case notifications, 2015  
Total cases notified 103
Total new and relapse 103
          - % tested with rapid diagnostics at time of diagnosis 38%
          - % with known HIV status 64%
          - % pulmonary 98%
          - % bacteriologically confirmed among pulmonary 66%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.1 (0.05–0.16)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 15 23%
          - on antiretroviral therapy 15 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  2
(0–5)
Estimated % of TB cases with MDR/RR-TB 1.7% (0.04–9.1) 0% (0–0)  
% notified tested for rifampicin resistance 38% 25% 39
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 18% 89
Previously treated cases, excluding relapse, registered in 2014   0
HIV-positive TB cases, all types, registered in 2014 5% 19
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
54% (40–83)
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data